| Popis: |
Completion of the human genome project together with continuing efforts to identify underlying genetic drivers of disease have led to tremendous advances in the discovery of novel therapeutics. In oncology, FDA approval last year of the kinase inhibitors vemurafenib and crizotinib, targeting the mutant BRAF V600E and the EML4-ALK fusion protein, respectively, has heralded the era of truly personalized medicine for patients with solid tumors. Nonetheless, there is recognition that genetic alteration alone does not always result in a given disease phenotype, and the role of epigenetic regulation of gene transcription is also seen as increasingly critical. Indeed, normal and/or aberrant cellular behavior is likely a consequence of an integrated influence of both genomic and epigenomic aspects. |
